This phase II trial is evaluating whether a new drug (INCB050465) will be an effective treatment option for patients with follicular lymphoma who have gotten worse or not responded on other therapies.
This trial is treating patients with Follicular Lymphoma.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor in Relapsed or Refractory Follicular Lymphoma
In this phase II trial, participants will be randomized into one of two groups. In Group A, participants will receive INCB050465 once daily (QD) for 8 weeks followed by INCB050465 once weekly. In Group B, participants will receive INCB050465 once daily (QD).
Recruiting Hospitals Read More